Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.

Date publication

octobre 2022

Journal

British journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DESMOULINS Isabelle

Tous les auteurs :
Jacot W, Lusque A, Vicier C, Mailliez A, de La Motte Rouge T, Cabel L, Levy C, Patsouris A, Desmoulins I, Uwer L, Thery JC, Robain M, Caron O, Tredan O, Filleron T, Frenel JS, Delaloge S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36207609

Résumé

The efficacy and added benefit of platinum-based chemotherapy (PtCT) for metastatic breast cancer (MBC) remain unclear in patients with and without germline BRCA1 or BRCA2 mutations (gBRCA1/2m and gBRCA1/2wt, respectively).

Référence

Br J Cancer. 2022 10 7;: